title: Inflammation and neurological adverse drugs reactions: a case of long lasting impaired consciousness after oxatomide administration in a patient with gastroenteritis.
abstract: Oxatomide at therapeutic doses generates occasionally drowsiness in children. When administered at toxic doses, however oxatomide may induce long lasting impaired consciousness. We now report a case of severe long lasting impaired consciousness induced by therapeutic doses of oxatomide occurring in a child affected by acute gastroenteritis. The clinical symptoms, the pharmacogenetic tests of polymorphisms in cytochrome P450 metabolizing enzymes (CYPs) and the clinical and laboratory analyses indicate that the enhanced drug sedative effect is likely due to an acute, yet mild, inflammatory state of the patient. These findings highlight the importance of assessing common, not serious inflammatory states when oxatomide is prescribed in paediatric patients.
authors.affiliation: Unit of Clinical Pharmacology, Department of Clinical Sciences, University Hospital Luigi Sacco, Università di Milano, 20157 Milan, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Antoniazzi
authors.forename: Dario
authors.initials: D
authors.lastname: Cattaneo
authors.forename: Valentina
authors.initials: V
authors.lastname: Perrone
authors.forename: Carla
authors.initials: C
authors.lastname: Carnovale
authors.forename: Simonetta
authors.initials: S
authors.lastname: Cherubini
authors.forename: Maria Carmela
authors.initials: MC
authors.lastname: Mugolino
authors.forename: Francesco
authors.initials: F
authors.lastname: Clementi
authors.forename: Gianvincenzo
authors.initials: G
authors.lastname: Zuccotti
authors.forename: Emilio
authors.initials: E
authors.lastname: Clementi
authors.forename: Sonia
authors.initials: S
authors.lastname: Radice
mesh_terms: D018926:Anti-Allergic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002675:Child, Preschool; D003231:Conjunctivitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D003244:Consciousness Disorders / Q000139:chemically induced* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004421:Dystonia / Q000139:chemically induced / Q000503:physiopathology; D005500:Follow-Up Studies; D005759:Gastroenteritis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D008297:Male; D009460:Neurologic Examination; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index; D013997:Time Factors
chemical_list: D018926:Anti-Allergic Agents; D010879:Piperazines; C015408:oxatomide